A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDSUlrich Keilholz, Carmen Scheibenbogen, Anne Letsch et al.|Blood|2009Cited by 300
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological TherapyUlrich Keilholz, Michael B. Atkins, W. Martin Kast et al.|Journal of Immunotherapy|2002Cited by 299
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemiaCarmen Scheibenbogen, Ulrich Keilholz, Anne Letsch et al.|Blood|2002Cited by 251
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.Ulrich Keilholz, Alexander M.M. Eggermont, S.H. Goey et al.|Journal of Clinical Oncology|1997Cited by 196
Natural T cell immunity against cancer.Dirk Nagorsen, Ulrich Keilholz, Carmen Scheibenbogen et al.|PubMed|2003Cited by 196